Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.

[1]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[2]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[3]  J. Bluestone,et al.  Cloning of an interleukin-4 inducible gene from cytotoxic T lymphocytes and its identification as a lipase , 1990, Cell.

[4]  T. Boon,et al.  Structure of the gene of tum− transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells , 1989, Cell.

[5]  S. Schreiber,et al.  Transmembrane channels based on tartaric acid-gramicidin A hybrids. , 1989, Science.

[6]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[7]  M. Bevan,et al.  Introduction of soluble protein into the class I pathway of antigen processing and presentation , 1988, Cell.

[8]  M. Sitkovsky,et al.  B cell stimulatory factor 1 (IL-4) enhances the development of cytotoxic T cells from Lyt-2+ resting murine T lymphocytes. , 1988, Journal of immunology.

[9]  H. Karasuyama,et al.  Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors , 1988, European journal of immunology.

[10]  K. Grabstein,et al.  Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor , 1987, Nature.

[11]  E. Shevach,et al.  B cell stimulatory factor 1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes , 1987, The Journal of experimental medicine.

[12]  W. Paul,et al.  B-cell stimulatory factor-1/interleukin 4. , 1987, Annual review of immunology.

[13]  R. Tsien,et al.  Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes , 1987, Nature.

[14]  B. Jordan,et al.  H—2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide , 1986, Nature.

[15]  R. Fernandez-Botran,et al.  Interleukin 4 mediates autocrine growth of helper T cells after antigenic stimulation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. McMichael,et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.

[17]  R. Wiltrout,et al.  Role of natural killer activity in development of spontaneous metastases in murine renal cancer. , 1985, The Journal of urology.

[18]  W. Paul,et al.  Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1 , 1985, Nature.

[19]  K. A. Wall,et al.  Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. , 1983, Journal of immunology.

[20]  D. Baltimore,et al.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus , 1983, Cell.

[21]  A. Glasebrook,et al.  IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. , 1980, Journal of immunology.

[22]  G. Galfré,et al.  Mac‐1: a macrophage differentiation antigen identified by monoclonal antibody , 1979, European journal of immunology.

[23]  M. Wigler,et al.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Hewitt,et al.  A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. , 1976, British Journal of Cancer.

[25]  G. Murphy,et al.  A murine renal cell carcinoma. , 1973, Journal of the National Cancer Institute.

[26]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.